Downloadable slide sets from key studies and clinical trials in people with diabetes
Real-world evidence
Three European retrospective real-world chart review studies to determine the effectiveness of flash glucose monitoring on HbA1c in adults with type 2 diabetes
This slide set details a chart-review study involving three European countries, showing significantly reduced glycated hemoglobin in adults with insulin-dependent type 2 diabetes after 3 to 6 months of flash glucose monitoring. Source: Kröger J, Fasching P, Hanaire H. Diabetes Ther 2020; 11: 279–291
Funded by an educational grant from Abbott Diabetes Care
The impact of flash glucose monitoring on glycaemic control as measured by HbA1c: a meta-analysis of clinical trials and real-world observational studies
These slides describe a meta-analysis of randomized trials and real-world studies, confirming reductions in glycated hemoglobin in children and adults with type 1 diabetes and adults with type 2 diabetes using flash glucose monitoring. Source: Evans M, Welsh Z, Ells S, Seibold A. Diabetes Ther 2020; 11: 83–95
Funded by an educational grant from Abbott Diabetes Care
These slides detail a study of flash glucose monitoring in children and adolescents, showing good accuracy relative to capillary blood glucose testing during up to 14 days of use, along with high acceptability of the device. Source: Edge J, Acerini C, Campbell F, et al. Arch Dis Child 2017; 102: 543–549
Funded by an educational grant from Abbott Diabetes Care
The study outlined in this slide set showed improved time in optimal blood glucose range and greater treatment satisfaction among children and adolescents with type 1 diabetes using flash glucose monitoring compared with self-monitoring. Source: Campbell FM, Murphy NP, Stewart C, Biester T, Kordonouri O. Pediatr Diabetes 2018; 19: 1294–1301
Funded by an educational grant from Abbott Diabetes Care
This slide set describes a study of flash glucose monitoring in pregnant women with diabetes, which demonstrates clinical accuracy versus self-monitoring of blood glucose and a high level of acceptability by the patients. Source: Scott EM, Bilous RW, Kautzky-Willer A. Diabetes Technol Ther 2018; 20: 180–188
Funded by an educational grant from Abbott Diabetes Care
This slide set outlines the extension phase of the REPLACE trial, which shows that the significant reductions in hypoglycemia obtained in patients with insulin-dependent type 2 diabetes after 6 months of flash glucose monitoring use were sustained over an additional 6 months. Source: Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Diabetes Ther 2017; 8: 573–586
Funded by an educational grant from Abbott Diabetes Care
This slide set presents trial findings showing that patients with well-controlled type 1 diabetes who undergo flash glucose testing achieve a greater reduction in the time spent in hypoglycemia over 6 months than those who carry out standard self-monitoring. Source: Bolinder J, Antuna R, Geelhoed-Duijvestijn P, et al. Lancet 2016; 388: 2254–2263
Funded by an educational grant from Abbott Diabetes Care
This slide set outlines the results of an open-label trial suggesting that the use of flash glucose-sensing technology results in similar changes in glycated hemoglobin over 6 months compared with standard self-monitoring among insulin-treated patients with type 2 diabetes. Source: Haak T, Hanaire H, Ajjan R, et al. Diabetes Ther 2017; 8: 55–73
Funded by an educational grant from Abbott Diabetes Care
This slide set describes the results of a subgroup analysis of the IMPACT study, which demonstrates that the use of flash glucose technology is associated with a significant reduction in the time spent in hypoglycemia among patients with well-controlled type 1 diabetes treated with multiple daily injections. Source: Oskarsson P, Antuna R, Geelhoed-Duijvestijn P, et al. Diabetologia 2018; 61: 539–550
Funded by an educational grant from Abbott Diabetes Care
